Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 3 2Phase 2 2Phase 1 2

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

Octreotide 2Cabergoline 2pegvisomant 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Acromegaly × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Novartis

Phase 4 Completed
20 enrolled

Acromegaly

Data powered by HemOnc (CC BY 4.0) Colophon âš¡